Novartis increases stake in stem cell group – PharmaTimes
Medical Daily |
Novartis increases stake in stem cell group
PharmaTimes Novartis is investing a further $15 million in Israeli stem cell specialist Gamida after turning down a buyout option earlier this year. This increases Novartis' stake in the company by 2.5 percent. The investment will be used to advance Gamina's … Novartis Will Invest another $15 Million in Gamida Cell Totaling to $50M … Novartis Buys Another 2.5% In Israel's Gamida Cell The Ticker: Tel Aviv Shares Trade Quietly Despite Unrest |
